Geoffrey Von Maltzahn

Our Gene Writing™ technology advances genetic medicine beyond its current limitations. Learn more at http://TesseraTherapeutics.com

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

Pioneering generative biology to create breakthrough therapeutics.

We are unyielding in our pursuit of life-changing therapies and our grit and compassion lead us to fight for a better future for patients and their families. We believe there is tremendous potential in the area of targeting the immune system through the gut microbiome. By working with the microbiome rather than replacing it, Kaleido is in a unique position to unlock an untapped area of science with unprecedented new treatments.

Our Gene Writing™ technology advances genetic medicine beyond its current limitations. Learn more at http://TesseraTherapeutics.com

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

Pioneering generative biology to create breakthrough therapeutics.

We are unyielding in our pursuit of life-changing therapies and our grit and compassion lead us to fight for a better future for patients and their families. We believe there is tremendous potential in the area of targeting the immune system through the gut microbiome. By working with the microbiome rather than replacing it, Kaleido is in a unique position to unlock an untapped area of science with unprecedented new treatments.